Jae Werndli

525 total citations
16 papers, 396 citations indexed

About

Jae Werndli is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Jae Werndli has authored 16 papers receiving a total of 396 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pathology and Forensic Medicine, 11 papers in Oncology and 5 papers in Genetics. Recurrent topics in Jae Werndli's work include Lymphoma Diagnosis and Treatment (12 papers), Viral-associated cancers and disorders (5 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Jae Werndli is often cited by papers focused on Lymphoma Diagnosis and Treatment (12 papers), Viral-associated cancers and disorders (5 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Jae Werndli collaborates with scholars based in United States and Czechia. Jae Werndli's co-authors include Brad S. Kahl, Natalie S. Callander, KyungMann Kim, Thomas McFarland, Walter Longo, Jules H. Blank, Stephanie Markovina, Jens C. Eickhoff, Shigeki Miyamoto and Shelby L. O’Connor and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Jae Werndli

15 papers receiving 390 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Jae Werndli 223 198 142 135 129 16 396
Marius Giurescu 168 0.8× 292 1.5× 177 1.2× 56 0.4× 161 1.2× 26 501
Christina Liu 133 0.6× 172 0.9× 240 1.7× 53 0.4× 147 1.1× 14 465
Daisy Moreno 70 0.3× 61 0.3× 178 1.3× 201 1.5× 174 1.3× 9 430
Viralkumar Patel 117 0.5× 71 0.4× 120 0.8× 61 0.5× 182 1.4× 11 349
Елена Бибикова 236 1.1× 69 0.3× 185 1.3× 153 1.1× 326 2.5× 16 525
Adekunle Raji 76 0.3× 156 0.8× 218 1.5× 56 0.4× 29 0.2× 17 395
Sandrine Degryse 95 0.4× 141 0.7× 156 1.1× 211 1.6× 112 0.9× 11 485
Rita Andraos 49 0.2× 129 0.7× 282 2.0× 98 0.7× 120 0.9× 7 411
Karl Hsu 38 0.2× 168 0.8× 255 1.8× 101 0.7× 44 0.3× 14 433
Anja Pedersen 247 1.1× 182 0.9× 60 0.4× 12 0.1× 152 1.2× 8 317

Countries citing papers authored by Jae Werndli

Since Specialization
Citations

This map shows the geographic impact of Jae Werndli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jae Werndli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jae Werndli more than expected).

Fields of papers citing papers by Jae Werndli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jae Werndli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jae Werndli. The network helps show where Jae Werndli may publish in the future.

Co-authorship network of co-authors of Jae Werndli

This figure shows the co-authorship network connecting the top 25 collaborators of Jae Werndli. A scholar is included among the top collaborators of Jae Werndli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jae Werndli. Jae Werndli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Chang, Elizabeth, Lakeesha Carmichael, KyungMann Kim, et al.. (2017). VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. Clinical Lymphoma Myeloma & Leukemia. 18(1). e61–e67. 11 indexed citations
2.
Chang, Julie, Christopher G. Peterson, Lakeesha Carmichael, et al.. (2016). Durable Remissions with the VcR-CVAD Regimen for Mantle Cell Lymphoma (MCL), Regardless of Age: Long-Term Follow-up of a Wisconsin Oncology Network (WON) Study. Blood. 128(22). 149–149. 2 indexed citations
3.
Chang, Elizabeth, Thomas C. Havighurst, KyungMann Kim, et al.. (2016). Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study. British Journal of Haematology. 173(2). 283–291. 8 indexed citations
4.
5.
Chang, Elizabeth, Christopher G. Peterson, Sangbum Choi, et al.. (2011). VcR‐CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. British Journal of Haematology. 155(2). 190–197. 43 indexed citations
6.
Kenkre, Vaishalee P., Jens C. Eickhoff, Jules H. Blank, et al.. (2011). Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leukemia & lymphoma. 52(9). 1675–1680. 30 indexed citations
7.
Chang, Julie, Jae Werndli, Wayne A. Bottner, et al.. (2010). Rituximab and CHOP Chemotherapy Plus GM-CSF for Previously Untreated Diffuse Large B-Cell Lymphoma in the Elderly: A Wisconsin Oncology Network Study. Clinical Lymphoma Myeloma & Leukemia. 10(5). 379–384. 13 indexed citations
8.
Callander, Natalie S., Stephanie Markovina, Mark Juckett, et al.. (2009). The Addition of Bevacizumab (B) to Lenalidomide and Low Dose Dexamethasone Does Not Significantly Increase Response in Relapsed or Refractory Multiple Myeloma (NCI#7317).. Blood. 114(22). 3885–3885. 16 indexed citations
9.
Markovina, Stephanie, Natalie S. Callander, Shelby L. O’Connor, et al.. (2008). Bortezomib-Resistant Nuclear Factor-κB Activity in Multiple Myeloma Cells. Molecular Cancer Research. 6(8). 1356–1364. 118 indexed citations
10.
11.
Kahl, Brad S., Julie Chang, Jens C. Eickhoff, et al.. (2008). VcR-CVAD Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma: A Phase II Study from the Wisconsin Oncology Network. Blood. 112(11). 265–265. 14 indexed citations
12.
Kahl, Brad S., Christopher G. Peterson, Jules H. Blank, et al.. (2007). A feasibility study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma. Journal of Clinical Oncology. 25(18_suppl). 8062–8062. 4 indexed citations
13.
Markovina, Stephanie, Shigeki Miyamoto, Walter Longo, et al.. (2007). Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM).. Blood. 110(11). 1173–1173. 13 indexed citations
14.
Kahl, Brad S., Walter Longo, Jens C. Eickhoff, et al.. (2006). Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Annals of Oncology. 17(9). 1418–1423. 82 indexed citations
15.
Kahl, Brad S., Howard H. Bailey, KyungMann Kim, et al.. (2005). Phase II Study of Weekly Low-Dose Paclitaxel for Relapsed and Refractory Non-Hodgkin's Lymphoma: A Wisconsin Oncology Network Study. Cancer Investigation. 23(1). 13–18.
16.
Kahl, Brad S., Howard H. Bailey, KyungMann Kim, et al.. (2005). Phase II Study of Weekly Low-Dose Paclitaxel for Relapsed and Refractory Non-Hodgkin's Lymphoma: A Wisconsin Oncology Network Study. Cancer Investigation. 23(1). 13–18. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marius Giurescu Breakdown of academic impact, for papers by Christina Liu Breakdown of academic impact, for papers by Daisy Moreno Breakdown of academic impact, for papers by Viralkumar Patel Breakdown of academic impact, for papers by Елена Бибикова Breakdown of academic impact, for papers by Adekunle Raji Breakdown of academic impact, for papers by Sandrine Degryse Breakdown of academic impact, for papers by Rita Andraos Breakdown of academic impact, for papers by Karl Hsu Breakdown of academic impact, for papers by Anja Pedersen
Rankless by CCL
2026